Abstract:BackgroundDNA methylation mediates gene silencing primarily by inducing repressive chromatin architecture via a common theme of interaction involving methyl-CpG binding (MBD) proteins, histone modifying enzymes and chromatin remodelling complexes. Hence, targeted inhibition of MBD protein function is now considered a potential therapeutic alternative for thwarting DNA hypermethylation prompted neoplastic progress. We have analyzed the gene and protein expression level of the principal factors responsible for gene silencing, that is, DNMT and MBD proteins in MCF-7 and MDA-MB-231 breast cancer cell lines after treatment with various epigenetic drugs.ResultsOur study reveals that the epigenetic modulators affect the expression levels at both transcript and protein levels as well as encourage growth arrest and apoptosis in MCF-7 and MDA-MB-231 cells. AZA, TSA, SFN, and SAM inhibit cell growth in MCF-7 and MDA-MB-231 cell lines in a dose-dependent manner, that is, with increasing concentrations of drugs the cell viability gradually decreases. All the epigenetic modulators promote apoptotic cell death, as is evident form increased chromatin condensation which is a distinct characteristic of apoptotic cells. From FACS analysis, it is also clear that these drugs induce G2-M arrest and apoptosis in breast cancer cells. Further, transcript and protein level expression of MBDs and DNMTs is also affected - after treatment with epigenetic drugs; the level of transcripts/mRNA of MBDs and DNMTs has consistently increased in general. The increase in level of gene expression is substantiated at the protein level also where treated cells show higher expression of DNMT1, DNMT3A, DNMT3B, and MBD proteins in comparison to untreated cells. In case of tissue samples, the expression of different DNMTs is tissue stage-specific. DNMT1 exhibits significantly higher expression in the metastatic stage, whereas, DNMT3A and DNMT3B have higher expression in the primary stage in comparison to the metastatic samples.ConclusionThe epigenetic modulators AZA, TSA, SFN, and SAM may provide opportunities for cancer prevention by regulating the components of epigenetic gene-silencing machinery especially DNMTs and MBDs.

Distinct Effects on Gene Expression of Chemical and Genetic Manipulation of the Cancer Epigenome Revealed by a Multimodality Approach

The effects of 5-Aza-2-deoxycytidine, a methylation inhibitor, on the proliferation of androgen-sensitive prostate cancer cell line, and on the regulation of methylation of glutathione s-transferase P1 and retinoic acid receptorβ2 gene

Effects of Epigenetic Drugs on BRCA1 and CHD5 Expressions in Breast Cancer Cells

Differential induction of apoptosis and senescence by the DNA methyltransferase inhibitors 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumor cells

Integrated Epigenetics of Human Breast Cancer: Synoptic Investigation of Targeted Genes, Micrornas and Proteins Upon Demethylation Treatment.

Microarray analysis of gene expression in metastatic gastric cancer cells after incubation with the methylation inhibitor 5-aza-2′-deoxycytidine

Epigenetic Modification Regulates Both Expression of Tumor-Associated Genes and Cell Cycle Progressing in Human Colon Cancer Cell Lines: Colo-320 and SW1116.

Epigenomic manipulation reveals the relationship between locus specific chromatin dynamics and gene expression

Regulation of DNA Methylation on Expression of Genes in Human Gastric Cancer Cell Lines

Potential advantages of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer therapy

Effects of Dna Methylation on Expression of Tumor Suppressor Genes and Proto-Oncogene in Human Colon Cancer Cell Lines

Expression profiling of DNA methylation-mediated epigenetic gene-silencing factors in breast cancer

Chemical Regulation of Epigenetic Modifications: Opportunities for New Cancer Therapy

DNA Methylation Targeting: The DNMT/HMT Crosstalk Challenge

DNA Methylation and Histone Deacetylation: Interplay and Combined Therapy in Cancer

DNA Hypermethylation As a Chemotherapy Target.

Genomic DNA Hypomethylation by Histone Deacetylase Inhibition Implicates DNMT1 Nuclear Dynamics

A multiomics approach reveals RNA dynamics promote cellular sensitivity to DNA hypomethylation

Uncoordinated expression of DNA methylation-related enzymes in human cancer

Abstract 7106: Distinct functions of EHMT1 and EHMT2 in cancer chemotherapy and immunotherapy

The Demethylating Agent 5-Aza-2'-deoxycytidine Prevents Tumorigenesis in a Mouse Model of Colorectal Cancer